Why Is TWIST BIOSCIENCE COR (TWST) Stock Down Today?

Twist Bioscience (TWST) shares fell 9.30% to $111.19 on November 12, 2026. The decline followed the company’s fourth-quarter earnings report, where revenue beat expectations but the fiscal 2027 outlook was viewed as underwhelming by the market.

What Happened

Twist Bioscience reported Q4 GAAP EPS of -$0.32, beating estimates by $0.06, alongside revenue of $126.6 million, which represented 27% growth. The company recorded a net loss of $130.2 million, or $2.08 per diluted share, compared to a net loss of $77.7 million, or $1.30 per diluted share, in the prior year. Despite the quarterly beat, the stock slipped after the company provided its fiscal 2027 outlook. Management projected total sales between $550 million and $560 million, which was slightly below the consensus estimate of $548.67 million. For the first quarter of 2027, the company guided revenue to $130 million to $132 million, exceeding the consensus estimate of $126.42 million. The guidance was attributed in part to an AI-driven drug discovery boost.

What The Data Shows

The stock opened at $124.00, a 1.2% gap up from the prior close of $122.59. The session high was $124.00 at 7:00 AM ET, while the session low reached $93.68 at 9:30 AM ET. Volume so far stands at 2.2 million shares, which is 1.1 times the three-month daily average. The company has a market cap of $8.3 billion and remains unprofitable with a trailing twelve-month EPS of -$2.23. Revenue has grown 19.2% over the trailing twelve months, while the net margin stands at -31.7%. The stock has a beta of 2.22 and a 52-week range of $23.30 to $219.71. On November 12, the stock printed 16 fresh 52-week highs and 3 fresh 52-week lows. Over the last 8 sessions, the stock moved -5.0% from $129.04 to $122.59. Recent insider activity shows 0 buys and 34 sells totaling $102.6 million in the last 90 days, with the most recent filing on November 5, 2026.

What To Watch

Investors will monitor the company’s execution against its fiscal 2027 revenue guidance of $550 million to $560 million. The breadth of coverage, with 16 stories from 6 sources in the last 36 hours, indicates significant attention to the company’s forward-looking statements.